Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Control of malignant metastases by ICRF l59.

× No keyword cloud information.

27 in total

1. Effect of ICRF 159 on immune responses.

Authors: K Hellmann
Journal: Proc R Soc Med Date: 1972-03

2. Combined treatment of the Walker tumour with radiotherapy and ICRF 159.

Authors: K Norpoth; A Schaphaus; H Ziegler; U Witting
Journal: Z Krebsforsch Klin Onkol Cancer Res Clin Oncol Date: 1974

3. Vascular changes in tumours after treatment with ICRF 159.

Authors: A W Le Serve; K Hellmann
Journal: Br J Pharmacol Date: 1971-10 Impact factor: 8.739

4. Drug-induced inhibition of tumour cell dissemination.

Authors: K Burrage; K Hellmann; A J Salsbury
Journal: Br J Pharmacol Date: 1970-05 Impact factor: 8.739

5. Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic.

Authors: A J Salsbury; K Burrage; K Hellmann
Journal: Br Med J Date: 1970-11-07

Review 6. [Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report].

Authors: W Rhomberg; M Grass
Journal: Strahlenther Onkol Date: 1999-03 Impact factor: 3.621

7. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors: Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal: J Immunol Date: 2012-12-07 Impact factor: 5.422

8. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.

Authors: T Narita; S Yaguchi; T Komatsu; M Takase; A Hoshino; M Inaba; S Tsukagoshi
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

9. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colo-rectal cancer. Report of a controlled randomised study of 603 patients.

Authors: R D Kingston; J W Fielding; M K Palmer
Journal: Int J Colorectal Dis Date: 1993-07 Impact factor: 2.571

10. Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.

Authors: S L Maloney; D C Sullivan; S Suchting; J M J Herbert; E M Rabai; Z Nagy; J Barker; S Sundar; R Bicknell
Journal: Br J Cancer Date: 2009-09-15 Impact factor: 7.640